US Patent

US7754731 — Potassium salt of an HIV integrase inhibitor

Method of Use · Assigned to Merck Sharp and Dohme LLC · Expires 2029-03-11 · 3y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects the potassium salt of Compound A, an HIV integrase inhibitor used to treat or prevent HIV infection and delay the onset of AIDS.

USPTO Abstract

Potassium salts of Compound A and methods for their preparation are disclosed, wherein Compound A is of formula: Compound A is an HIV integrase inhibitor useful for treating or prophylaxis of HIV infection, for delaying the onset of AIDS, and for treating or prophylaxis of AIDS.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-257`	—	raltegravir-potassium
`U-257`	—	raltegravir-potassium
`U-1663`	—	Epivir
`U-257`	—	raltegravir-potassium
`U-257`	—	raltegravir-potassium
`U-257`	—	raltegravir-potassium

Patent Metadata

Patent number: US7754731
Jurisdiction: US
Classification: Method of Use
Expires: 2029-03-11
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Merck Sharp and Dohme LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.